Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06679816 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

StatusRecruiting
PhasePhase 4
Started2024-12-04
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 14, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-01-13
notable
Not Yet Recruiting→Recruiting Study Status, Oversight, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-11-20→confirmed 2024-12-04
Study sites0→1
2024-11-06
minor
Original filing
The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms
Trial Details
NCT Number NCT06679816
Lead Sponsor Beijing Tiantan Hospital
Conditions Pituitary Adenoma, Pituitary Neuroendocrine Tumor
Enrollment 882 participants
Start Date 2024-12-04
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-14